Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs GLENMARK PHARMA - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES GLENMARK PHARMA ALKEM LABORATORIES/
GLENMARK PHARMA
 
P/E (TTM) x 26.6 12.2 217.9% View Chart
P/BV x 4.1 1.6 263.4% View Chart
Dividend Yield % 1.1 0.6 178.4%  

Financials

 ALKEM LABORATORIES   GLENMARK PHARMA
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-22
GLENMARK PHARMA
Mar-21
ALKEM LABORATORIES/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs4,068573 710.3%   
Low Rs2,671195 1,367.7%   
Sales per share (Unadj.) Rs889.4387.8 229.3%  
Earnings per share (Unadj.) Rs140.534.4 408.8%  
Cash flow per share (Unadj.) Rs166.050.1 331.2%  
Dividends per share (Unadj.) Rs34.002.50 1,360.0%  
Avg Dividend yield %1.00.7 155.0%  
Book value per share (Unadj.) Rs722.4249.6 289.4%  
Shares outstanding (eoy) m119.57282.17 42.4%   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x3.81.0 382.6%   
Avg P/E ratio x24.011.2 214.7%  
P/CF ratio (eoy) x20.37.7 264.9%  
Price / Book Value ratio x4.71.5 303.2%  
Dividend payout %24.27.3 332.7%   
Avg Mkt Cap Rs m402,868108,353 371.8%   
No. of employees `000NANA-   
Total wages/salary Rs m19,62723,437 83.7%   
Avg. sales/employee Rs Th00-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th00-  
INCOME DATA
Net Sales Rs m106,342109,439 97.2%  
Other income Rs m1,627502 323.9%   
Total revenues Rs m107,968109,941 98.2%   
Gross profit Rs m20,38021,289 95.7%  
Depreciation Rs m3,0404,436 68.5%   
Interest Rs m5243,531 14.8%   
Profit before tax Rs m18,44313,825 133.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6404,124 39.8%   
Profit after tax Rs m16,8039,701 173.2%  
Gross profit margin %19.219.5 98.5%  
Effective tax rate %8.929.8 29.8%   
Net profit margin %15.88.9 178.3%  
BALANCE SHEET DATA
Current assets Rs m84,35473,596 114.6%   
Current liabilities Rs m48,05342,010 114.4%   
Net working cap to sales %34.128.9 118.3%  
Current ratio x1.81.8 100.2%  
Inventory Days Days427 632.9%  
Debtors Days Days6586 75.4%  
Net fixed assets Rs m43,24567,093 64.5%   
Share capital Rs m239282 84.7%   
"Free" reserves Rs m86,13470,148 122.8%   
Net worth Rs m86,37370,430 122.6%   
Long term debt Rs m9438,888 0.2%   
Total assets Rs m127,599140,689 90.7%  
Interest coverage x36.24.9 736.8%   
Debt to equity ratio x00.6 0.2%  
Sales to assets ratio x0.80.8 107.1%   
Return on assets %13.69.4 144.4%  
Return on equity %19.513.8 141.2%  
Return on capital %21.915.9 138.2%  
Exports to sales %18.70-   
Imports to sales %00-   
Exports (fob) Rs m19,924NA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m19,92435,753 55.7%   
Fx outflow Rs m3,91112,023 32.5%   
Net fx Rs m16,01323,729 67.5%   
CASH FLOW
From Operations Rs m11,11011,312 98.2%  
From Investments Rs m-14,351-6,752 212.5%  
From Financial Activity Rs m3,796-4,418 -85.9%  
Net Cashflow Rs m580278 208.3%  

Share Holding

Indian Promoters % 57.1 46.7 122.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 19.8 34.7 56.9%  
FIIs % 5.7 24.2 23.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 42.9 53.4 80.3%  
Shareholders   84,104 312,473 26.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   DR. REDDYS LAB    SUN PHARMA    CIPLA    LUPIN    ZYDUS LIFESCIENCES    



Today's Market

Sensex Zooms 130 Points, Nifty Ends Above 17,600; Financial and IT Stocks Rally(Closing)

Indian benchmark indices ended on a positive note amid a highly volatile session. This was on the back of metal stocks along with banking and financials.